Ads
related to: lutetium oxodotreotide 177 mm pen injection treatment- Case Studies
Review real case studies
with real patients.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Case Studies
Search results
Results from the WOW.Com Content Network
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] It is a radiolabeled somatostatin analog. [3] [6] [7]
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...
Complete or partial treatment response has been seen in 20-30% of patients in trials treated with 177 Lu-DOTATATE or 90 Y-DOTATOC, among the most widely used PRRT drugs. [ 1 ] [ 11 ] [ 12 ] [ 13 ] When it comes to comparing these two PRRT, Y-labeled and Lu-labeled PRRTs, it appears that Y-labeled is more effective for larger tumors, while Lu ...
Forty radioisotopes have been characterized, with the most stable, besides 176 Lu, being 174 Lu with a half-life of 3.31 years, and 173 Lu with a half-life of 1.37 years. All of the remaining radioactive isotopes have half-lives that are less than 9 days, and the majority of these have half-lives that are less than half an hour.
Lutetium-177 labelled edotreotide (177 Lu-DOTA-TOC), with the trade name Solucin, is the subject of a phase 3 clinical trial for treatment of GEP-NETs. [ 7 ] [ 8 ] It was granted orphan drug designation by the European Medicines Agency in 2014.
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
An injector pen (also called a medication pen) is a device used for injecting medication under the skin. First introduced in the 1980s, injector pens are designed to make injectable medication easier and more convenient to use, thus increasing patient adherence .
Ads
related to: lutetium oxodotreotide 177 mm pen injection treatment